Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Multiple sclerosis (MS) is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the ...

Researchers have identified two compounds capable of repairing the protective myelin sheath damaged by multiple sclerosis, a major advance toward reversing nerve injury rather than just slowing it.

Zenas Biopharma has acquired global rights to develop BTK inhibitor orelabrutinib to treat progressive forms of multiple ...

The Valhalla Foundation awarded Octave Bioscience funding to further develop a biomarker blood test for assessing disease ...

A new study finds two neurology drugs cost less without insurance, revealing how complex drug pricing can make medicine more ...

The project builds on earlier research involving a compound called indazole chloride, known for promoting remyelination and modulating the immune system in mouse models of MS. While effective, ...

Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final ...

The company will use the funds to drive commercial growth, broaden its employer and payer programs, and accelerate AI ...